CLOVER HEALTH INVESTMENTS, CORP. /DE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CLOV in the last 7 days.
Clover Health (CLOV) released a Q2 2026 supplemental Q&A, highlighting Clover Assistant's impact on insurance profit and member health. CA-linked members showed higher profit and better health outcomes. The company is investing in growth, expecting leverage as membership increases. Counterpart Health's rollout aims to expand lives under management.
Pakistan Stock Exchange’s KSE-100 Index fell 2,546.94 points, or 1.41%, to close at 177,955.50. The session saw 511.87 million index shares traded and 563 stocks declining more than advancing. Cnergyico PK (CNERGY) led volume at 231.46 million shares, closing at Rs14.79. Hascol (HASCOL) and Sui Southern Gas (SSGC) also moved higher.
The article covers multiple market and company items. Exxon Mobil raised its quarterly dividend 4% to $1.03 per share, extending a 26-year payout streak. It also notes Varsal Tech’s NYSE American IPO pricing range of $5 to $6 on 3 million shares, and Fabrinet’s optical demand-driven revenue growth and guidance. Other sections discuss ETFs, board performance, and cloud/AI themes.
Recent CLOV coverage spans earnings, market movers and financial news.
In the last 30 days, CLOV insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($486K). The most active reporter was THORNTON JOSEPH CLAY, Interim CFO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive impact on profitability metrics may boost investor sentiment.
CLOV participated in the broad selloff, signaling weaker momentum and potential liquidity-driven pressure.
The article provides a price move reference but no company-specific new disclosure for Clover Health.
Strong guidance and EPS/revenue beats are being rewarded by the market.
Guidance upside plus improving BER and GAAP profitability suggests a higher earnings power trajectory, but CMS star-rating appeal risk remains.
alphai scores every news story that mentions CLOV with an AI model for sentiment and relevance, and aggregates insider trades from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Clover Health (CLOV) released a Q2 2026 supplemental Q&A, highlighting Clover Assistant's impact on insurance profit and member health. CA-linked members showed higher profit and better health outcomes. The company is investing in growth, expecting leverage as membership increases. Counterpart Health's rollout aims to expand lives under management.
1 min readPakistan Stock Exchange’s KSE-100 Index fell 2,546.94 points, or 1.41%, to close at 177,955.50. The session saw 511.87 million index shares traded and 563 stocks declining more than advancing. Cnergyico PK (CNERGY) led volume at 231.46 million shares, closing at Rs14.79. Hascol (HASCOL) and Sui Southern Gas (SSGC) also moved higher.
2 min readThe article covers multiple market and company items. Exxon Mobil raised its quarterly dividend 4% to $1.03 per share, extending a 26-year payout streak. It also notes Varsal Tech’s NYSE American IPO pricing range of $5 to $6 on 3 million shares, and Fabrinet’s optical demand-driven revenue growth and guidance. Other sections discuss ETFs, board performance, and cloud/AI themes.
6 min readA Q2 earnings roundup covers health insurers and related providers. CVS Health (CVS) reported $106.1B revenue (+7.3% YoY), beating EPS and full-year EPS guidance; shares fell 8.4% to $95.66. Progyny (PGNY) revenue was $350.5M (+5.3%), but guidance missed; stock down 7.8% to $27.87. Humana (HUM) revenue $40.87B (+26.2%) and Clover Health (CLOV) revenue $743.2M (+55.6%) both beat; CLOV rose 9.9% to $4.55.
7 min readClover Health (CLOV) reported Q2 2026 results on an earnings call. It said Medicare Advantage membership rose to 157,309 (+48% YoY), revenue was $743.2M (+55.6%), GAAP net income was $28M, and non-GAAP adjusted EBITDA was $40.9M. FY2026 guidance was raised to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA.
6 min readClover Health Investments (NASDAQ:CLOV) said its in-home care program enrollment rose 84% vs 2025, while total membership grew about 50%. The company retains full economic risk and expects cohort maturation to improve results in 2027-28. Clover guided for 2026 GAAP net income profitability with ~50% membership growth and submitted 4.5-star bids for 2027.
6 min readClover Health (2Q26 earnings call transcript) said first-half 2026 results included 48% MA membership growth, GAAP net income up $67 million YoY, and total revenue up more than $550 million YoY to $1.5 billion, with gross profit up $104 million. CEO cited Medicare Advantage Star rating recalculation to 4.5 stars for Payment Year 2027 after a court order, with CMS intending to appeal.
7 min readClover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.
6 min readClover Health (CLOV) shares rose about 12.7% to $4.67 after the company reported Q2 results showing profitability. Clover posted net income of $28.0 million on revenue of $743.2 million, its second straight profitable quarter, and raised 2026 guidance for revenue and adjusted EBITDA. The article also cites DOJ/SEC inquiries and CMS star-rating appeal.
4 min readA financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.
9 min read
